Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia

RegulatoryVebreltinibNegative

AI Analysis

Summary

Apollomics received a Nasdaq deficiency notice regarding failure to meet minimum market value requirements and announced updates regarding rights for its drug Vebreltinib (APL-101) in Asia.

Outcome Details

Nasdaq deficiency notice regarding minimum market value requirement

Importance:6/10

Sentiment:

-0.60

Nasdaqcompliancemarket_valuedeficiency_noticelicensing_update

Related Companies

$APLM

Read the original article

Published by yahoo_finance on June 24, 2026 8:15 PM

Read Original